Developing a New Class of Therapies Based on a Natural Cargo Carrier

One of the greatest challenges emerging therapies face is being able to reach the tissues and cells in the body where they need to go to provide benefit. Rather than using viral vectors or lipid nanoparticles, Evox is harnessing exosomes, a natural transporter within the body, to carry therapeutic cargo to desired targets. The company has developed platform technology to modify exosome so it can load therapeutic cargo into them to reach desired organs, the central nervous system, and intractable tissue. We spoke to Tony de Fougerolles, CEO of Evox Therapeutics, about exosomes, the company’s platform technology, and how it is using this approach to target a range of rare diseases.